Alfuzosin and Sildenafil interaction

Alfuzosin and Sildenafil: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.

Moderate

Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.

What the FDA labels say

From the Alfuzosin (Uroxatral) label · effective 2024-12-05

Moderate

Caution is advised for concomitant use of PDE5-inhibitors and UROXATRAL, as this combination can potentially cause symptomatic hypotension [see Drug Interactions (7.4) ].

Warnings and precautionsby drug classView label on DailyMed
Moderate

Concomitant use of PDE5 inhibitors with alpha adrenergic antagonists, including UROXATRAL, can potentially cause symptomatic hypotension ( 5.4 , 7.4 )

Drug interactionsby drug classView label on DailyMed
Moderate

PDE5 Inhibitors Caution is advised when alpha adrenergic antagonists, including UROXATRAL, are co-administered with PDE5 inhibitors.

Drug interactionsby drug classView label on DailyMed
Minor

Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators.

Warnings and precautionsby drug classView label on DailyMed
Minor

Alpha adrenergic antagonists and PDE5 inhibitors are both vasodilators that can lower blood pressure.

Drug interactionsby drug classView label on DailyMed

From the Sildenafil label · effective 2026-07-17

Moderate

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Hypotension when Co-administered with Alpha-blockers or Antihypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Consider the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

Warnings and precautionsby drug classView label on DailyMed
Moderate

In patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ) ] .

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.